New Study Reveals Best Way to Help Newborns Recovering from Opioid Exposure
A new multi-hospital study shows that a flexible, symptom-based approach helps newborns recovering from prenatal opioid exposure go home sooner.
When babies are exposed to opioids in the womb, they are at high risk for Neonatal Opioid Withdrawal Syndrome (NOWS). These infants usually experience sharp withdrawal symptoms during their first week of life. While nonpharmacological care and comfort measures—such as quiet rooms and swaddling—are typically the first line of defense, some babies still need medical intervention and a carefully tailored dose of medication to safely ease their symptoms. These pharmacological approaches have been shown to help manage symptoms and are recommended when supportive care alone is not enough.
Because there has been very little data on which medication strategy works best, researchers launched the OPTImize NOW study to compare two common approaches:
Symptom-based dosing: Giving a dose of medicine only when a baby’s specific withdrawal symptoms spike.
Scheduled taper: Giving medication on a strict, pre-set schedule and slowly weaning the baby off over time.
The study tracked infants across 23 hospitals in the United States. Hospitals were randomly assigned to use one of two methods: 1) starting with symptom-based dosing followed by a scheduled opioid tapering, or 2) starting with a scheduled opioid tapering followed by symptom-based dosing.
The results revealed that babies who received symptom-based dosing first were medically ready to leave the hospital significantly faster (averaging 9.18 days after birth, compared with 11.61 days with a scheduled taper). It is important to note that symptom-based dosing shortened the time to medical readiness for discharge, but did not significantly shorten infants’ overall hospital stays.
Researchers concluded that treating symptoms as they happen—rather than a long, rigid schedule of medication—allows doctors to respond to a child's changing needs and ultimately gets families home sooner.
The Study
Devlin, L. A., Babineau, D. C., Merhar, S. L., DeMauro, S. B., Kraft, W. K., Lorch, S. A., Das, A., McDonald, S. A., Rhodes, E., Schmidt, A. F., Trochinski, L., Crawford, M., Sithisarn, T., Leeman, L., Kovatis, K. Z., Ambalavanan, N., Smith, R. W., Telang, S., Tioseco, J. A., McAllister, J. M., … HEAL Evaluation of Limited Pharmacotherapies for Neonatal Opioid Withdrawal Syndrome (HELP for NOWS) Consortium (2026). Symptom-Based Dosing for Neonatal Opioid Withdrawal: The OPTimize NOW Randomized Clinical Trial. JAMA, 335(24), 2114–2125. https://doi.org/10.1001/jama.2026.5782
